Table 4

Comparison of treament and efficacy in different uveitis subtypes

Uveitis locationEfficacyDuring treatment with adalimumab*Previous anti-TNF treatment with insufficient response
NoneEtanercept†Infliximab‡
Primary anterior uveitisEffective4 (80%)310
Non-effective1 (20%)100
Anterior uveitis and SpAEffective19 (86%)1045
Non-effective2 (14%)101
Anterior uveitis and JIAEffective13 (76%)832
Non-effective4 (24%)310
Anterior uveitis and PsAEffective3 (75%)030
Non-effective1 (25%)010
Intermediate uveitis§Effective5 (100%)401
Non-effective0 (0%)000
Panuveitis¶Effective3 (100%)111
Non-effective0 (0%)000
Others**Effective2 (40%)110
Non-effective3 (60%)300
60 (100%)35 (58.3%)15 (25.0%)10 (16.7%)
  • *40 mg injection subcutaneously every other week.

  • †25 mg injection twice a week.

  • ‡3–5 mg/kg bodyweight—starting with upload.

  • §One patient with intermediate uveitis and rheumatoid arthritis, four patients without systemic disease.

  • ¶One patient with Behçet's, two patients without systemic disease.

  • **One patient with Behçet's and anterior uveitis (non-effective), two patients with anterior uveitis and rheumatoid arthritis (non-effective) and two patients with scleritis (effective).

  • JIA, juvenile idiopathic arthritis; PsA, psoriatic arthritis; SpA, spondylarthropathy; TNF, tumour necrosis factor.